ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Efficiency and safety of hepatic arterial infusion chemotherapy (HAIC) combined with anti-PD1 therapy versus HAIC monotherapy for advanced hepatocellular carcinoma: A multicenter propensity score matching analysis

Li, Yangyang; Liu, Wendao; Chen, Junwei; Chen, Yongxin; Guo, Jiandong; Pang, Huajin; Zhang, Wentao; An, Chao*; Li, Chengzhi*广东省人民医院; 南昌大学; 南方医科大学; 中山大学; 1
Cancer Medicine2024-1DOI: 10.1002/cam4.6836
10阅读
引用收藏
分享

摘要

Purpose: To investigate the clinical efficacy and safety of combination therapy of hepatic arterial infusion chemotherapy (HAIC) and anti-programmed cell death protein-1 (PD-1) therapy in the treatment of advanced hepatocellular carcinoma (HCC).Methods: In this retrospective clinical research, from March 2018 to December 2019, 1158 HCC patients categorized as BCLC stage C were reviewed for eligibility. We utilized propensity score matching (PSM) to mitigate initial disparities between the groups. The evaluation of the best tumor response was conducted in accordance with mRECIST 1.1 criteria. The difference in survival outcomes including overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) between groups were compared.Results: Following the eligibility review, 453 patients underwent a combined treatment of HAIC with PD1 inhibitors (HAIC-PD1 group), while 221 patients received HAIC monotherapy (HAIC group) met the inclusion criteria and were finally enrolled in this study. In the entire cohort, the HAIC-PD1 group exhibited significantly prolonged overall survival (median overall survival: 40.4 months vs. 9.7 months, p < 0.001) and progression-free survival (median progression-free survival: 22.1 months vs. 5.8 months, p < 0.001). By propensity score, patients were matched according to baseline differences, resulting in all 442 patients in group HAIC-PD1 (n = 221) and group HAIC (n = 221). After PSM adjustment, as well, the survival of the HAIC-PD1 group was still distinctly longer than the HAIC group (median overall survival time, 40.4 months vs 9.7 months, p < 0.001; median progression-free survival, 22.1 months vs 5.7 months, p < 0.001). Univariate and multivariable analysis demonstrated that AFP level, metastasis, and therapeutic schedule were independent predictive factors for overall survival.Conclusion: The combination therapy of HAIC and PD1 inhibitors successfully extended OS to advanced HCC patients and could be a better choice than HAIC monotherapy.

学科与关键词

关键词
hepatic arterial infusion chemotherapyhepatocellular carcinomaimmune checkpoint inhibitorspropensity score
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Cancer Medicine
发表日期
2024-01
卷期
第 13 卷, 第 1 期
DOI
10.1002/cam4.6836
语言
ENGLISH
成果收录
SCIE

作者

  • L

    Li, Yangyang (第一作者)

    1

  • L

    Liu, Wendao

    guangdong prov hosp · guangdong prov acad chinese med sci

查看全部 9 位作者收起作者
  • C

    Chen, Junwei

    sun yat sen univ

  • C

    Chen, Yongxin

    1

  • G

    Guo, Jiandong

    1

  • P

    Pang, Huajin

    southern med univ

  • Z

    Zhang, Wentao

    1 · nanchang univ

  • A

    An, Chao (通讯)

    sun yat sen univ

  • L

    Li, Chengzhi (通讯)

    1

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417